Ocaliva, a drug used to treat primary biliary cholangitis (PBC), has been linked to severe liver damage and death due to incorrect dosing. If you or a loved one was diagnosed with liver failure associated with an Ocaliva prescription, James F. Humphreys & Associates, L.C. can help you fight for the compensation that you deserve.
About Primary Biliary Cholangitis (PBC)
Primary biliary cholangitis is an autoimmune disorder where the immune system attacks the bile ducts. The bile ducts carry digestive fluid from the liver to the small intestine and are necessary for digestion. With PBC, chronic attacks on the bile duct can result in pain and damage to the bile ducts, leading to liver damage and failure.
Ocaliva is a medication prescribed to people suffering from PBC to prevent liver failure and the need for a liver transplant. Ocaliva works by preventing the build up of bile acid and increasing the movement of bile from the liver to the small intestine. This prevents a toxic and damaging accumulation of bile acid. However, Ocaliva was quickly found to be dangerous when prescribed at a higher dosage than recommended by Intercept Pharmaceuticals, the drug manufacturer. Intercept Pharmaceuticals has been sued for failing to adequately inform consumers of the possible side effects from Ocaliva.
If you or a loved one suffered from liver disease after taking Ocaliva, you may be entitled to compensation. Contact James F. Humphreys & Associates, L.C. to schedule a free consultation of your case today.
Toll Free: +1 (877) 341-2595
Although there have been reported injuries with this drug, the FDA has not withdrawn its approval at this time. Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death.